Emerging nano-scale delivery systems for the treatment of osteoporosis
Authors:
Open Access
- 13 July 2023
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 27 (1) , 1-25
Abstract
Osteoporosis is a pathological condition characterized by an accelerated bone resorption rate, resulting in decreased bone density and increased susceptibility to fractures, particularly among the elderly population. While conventional treatments for osteoporosis have shown efficacy, they are associated with certain limitations, including limited drug bioavailability, non-specific administration, and the occurrence of adverse effects. In recent years, nanoparticle-based drug delivery systems have emerged as a promising approach for managing osteoporosis. Nanoparticles possess unique physicochemical properties, such as a small size, large surface area-to-volume ratio, and tunable surface characteristics, which enable them to overcome the limitations of conventional therapies. These nanoparticles offer several advantages, including enhanced drug stability, controlled release kinetics, targeted bone tissue delivery, and improved drug bioavailability. This comprehensive review aims to provide insights into the recent advancements in nanoparticle-based therapy for osteoporosis. It elucidates the various types of nanoparticles employed in this context, including silica, polymeric, solid lipid, and metallic nanoparticles, along with their specific processing techniques and inherent properties that render them suitable as potential drug carriers for osteoporosis treatment. Furthermore, this review discusses the challenges and future suggestions associated with the development and translation of nanoparticle drug delivery systems for clinical use. These challenges encompass issues such as scalability, safety assessment, and regulatory considerations. However, despite these challenges, the utilization of nanoparticle-based drug delivery systems holds immense promise in revolutionizing the field of osteoporosis management by enabling more effective and targeted therapies, ultimately leading to improved patient outcomes.Keywords
Funding Information
- Ministry of Science and ICT (NRF-2022R1A2C3004850, NRF-2019M3A9H1032376, RS-2023-00208529)
- Ministry of Heath and Welfare (21C0703L1)
- Ministry of Health and Welfare (HI23C0689000023)
This publication has 186 references indexed in Scilit:
- Nanotechnology in the targeted drug delivery for bone diseases and bone regenerationInternational Journal of Nanomedicine, 2013
- Bioactive silica-based nanoparticles stimulate bone-forming osteoblasts, suppress bone-resorbing osteoclasts, and enhance bone mineral density in vivoNanomedicine: Nanotechnology, Biology and Medicine, 2012
- Functionalized Gold Nanoparticles and Their Biomedical ApplicationsNanomaterials, 2011
- Angiogenesis in bone regenerationInjury, 2011
- pH-Tunable Oxidase-Like Activity of Cerium Oxide Nanoparticles Achieving Sensitive Fluorigenic Detection of Cancer Biomarkers at Neutral pHAnalytical Chemistry, 2011
- Gold Nanoparticles Promote Osteogenic Differentiation of Mesenchymal Stem Cells through p38 MAPK PathwayACS Nano, 2010
- Bisphosphonates for the treatment of osteoporosis: insights for cliniciansTherapeutic Advances in Chronic Disease, 2010
- Titanium dioxide nanotubes enhance bone bonding in vivoJournal of Biomedical Materials Research Part A, 2009
- Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology PracticeThe Open Orthopaedics Journal, 2009
- Cell cycle molecules define a pathway required for neuron death in development and diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007